coronary artery disease
Conditions
Interventions
Percutaneous coronary intervention using everolimus-eluting stent
Percutaneous coronary intervention using paclitaxel-eluting stent
Sponsors
MY HOPE Project Office
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. hemodialysis patients 2. patients who are indicated for PCI with drug-eluting stents 3. patients who can recieve antiplatelet agents for at least 6 months after stent implantation 4. target lesion with the vessel 2.5-3.75mm in diameter 5. target lesion with the vessel < 46mm in length
Exclusion criteria
Exclusion criteria: 1. patients with acute myocardial infarction within 7 days 2. patients with neoplasm within 3 years 3. patients who are enrolled in an ongoing registry or clinical trial 4. patients with PCI within 6 months 5. patients who have chronic total occlusion 6. patients who have bifurcation lesion 7. patients who have restenotic lesion 8. patients who have lesion of bypass graft 9. nursing women or pregnant possible women 10. patients who have an allergy or hypersensitivity to everolimus and paclitaxel 11. patients who have side effects of antiplatelet agents or anticoaglants 12. patients who have severe liver dysfunction 13. patients disqualified from participation by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of binary restenosis | — |
Secondary
| Measure | Time frame |
|---|---|
| the rate of major adverse cardiac events | — |
Countries
Japan
Contacts
Public ContactMasatoshi Miyahara
Mie Heart Center Department of Cardiology
Outcome results
None listed